Market Scope
As per the reports by MRFR, the hemophilia treatment market is likely to project a robust CAGR of 6.10% during the review timeframe from 2022 to 2027.
Market Drivers
Hemophilia refers to a genetic disorder, usually hereditary, where the patient's blood lacks the needed proteins that help in blood coagulation. The condition could be severe, moderate, and mild. The global market for hemophilia treatment has been witnessing massive growth over recent years due to the increasing number of hemophilia cases, favorable government schemes & aggressive campaigning in several countries, and varied availability of therapies and medications. However, the growth of the hemophilia treatment cost hemophilia treatment market is anticipated to be hampered by the complications involved in the replacement therapies and higher costs associated with the recombinant products.
Competitive Analysis
The global market for hemophilia treatment has a strong competitive landscape with a wide number of players spread worldwide. The market players adopt several new strategies such as mergers, acquisitions, partnerships, and product development to grow their business. The list of leading players in the hemophilia treatment market includes companies such as F. Hoffmann-La Roche AG., Kedrion, Ferring B.V., Bayer AG, Baxter International Inc., Sanofi S.A., Octapharma AG, Novo Nordisk A/S, Pfizer, Inc., CSL Behring, Biogen Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Co., Ltd., and many others.
Recent Developments
- October 2021- Takeda Pharmaceutical has signed an R&D alliance with Poseida Therapeutics to access the company's several non-viral gene therapy technologies. The primary six programs for the alliance come from Poseida's pipeline and comprise the biotech's most advanced gene therapy program, P-FVIII-101, a preclinical candidate for the inherited blood clotting disorder hemophilia A.
Segment Analysis
The global Hemophilia Treatment market for hemophilia treatment is divided into several segments based on diagnosis, treatment, product, distribution channel, and region.
Based on the diagnosis, the hemophilia treatment market is divided into gene therapy and replacement therapy.
Based on treatment, the global market for hemophilia treatment is divided into gene therapy, antifibrinolytic agents, desmopressin, recombinant coagulation factor concentrates, and plasma-derived coagulation factor concentrate.
Based on the product, the hemophilia treatment market is split into antifibrinolytic agents, desmopressin, von Willebrand factor, factor IX, factor VIII, recombinant coagulation factor concentrates, von willebrand factor, activated prothrombin complex concentrate, factor XIII, factor IX, factor VIII, and plasma-derived coagulation factor concentrates.
The hemophilia treatment market is bifurcated into retail pharmacy, hospital pharmacy, and others by distribution channel.
Regional Analysis
The global market for hemophilia treatment is studied mainly across five regions: North America, South America, Asia-Pacific, Europe, and the Middle East & Africa.
The North American regional hemophilia treatment market has held the leading position in the market globally. The major aspect driving the regional market's growth is the rising number of collaborations and partnerships with leading market players. In addition, the technological advances in the products and therapeutic methods and the growing awareness of the condition among people have also contributed to the regional market's growth over recent times. Association of America has extended its market growth by providing co-pay initiatives to acquire uninterrupted treatment. Lately, the developments in gene therapy, which aim for coagulation factors, have positively impacted the growth of the hemophilia treatment market in the North American region.
The Asia-pacific regional hemophilia treatment market is anticipated to secure the second position in the global market. The increasing favorable reimbursement policies are driving the growth of the regional market. China is emerging to be the major market in the region. It announced 80% of the Hemophilia treatment in the region had been covered under health insurance that recorded for more than USD 16,000 in 2012. Since then, the rise in favorable schemes has been seen in China.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
United States of America
No comments:
Post a Comment